News

On June 27th, celebrity and cultural advocate Miss Lawrence returned to Atlanta with Plated Purpose, an immersive dining ...
Despite recent ASCO and FDA guidance recommending the inclusion of people living with HIV in pivotal cancer trials, nearly 75 ...
Anal cancer screening among men who have sex with men with HIV aged 35 years and older appeared cost-effective and could decrease anal cancer incidence and mortality, according to research published ...
Thirty-five years ago, the multimillion dollar fundraiser Seventh on Sale propelled the fashion industry into a new era of ...
The US Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV.
Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...
FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be taken twice a year. On Wednesday, the U.S. Food and Drug ...
By Dennis Thompson HealthDay ReporterFRIDAY, June 20, 2025 (HealthDay News) — A cheap HIV drug might be able to help people with diabetes reverse a complication that can lead to blindness, a new ...
JACKSON, Miss. — The FDA has approved Yeztugo, the world’s first twice-a-year shot to prevent HIV infection, marking a significant advancement in HIV prevention. The new treatment is expected to be a ...
FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect Efficacy With 99.9% of Pa ...
Medications to prevent HIV, known as pre-exposure prophylaxis or PrEP, are widely available. But most are daily pills, including low-cost generic versions of Gilead's older drug Truvada, that require ...
Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one dose. By combining two immune-boosting adjuvants alum ...